Pertussis inflammation is mediated by a balance between peptidoglycan recognition proteins-1 and -4
百日咳炎症是由肽聚糖识别蛋白-1 和 -4 之间的平衡介导的
基本信息
- 批准号:10556372
- 负责人:
- 金额:$ 38.63万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-02-01 至 2027-01-31
- 项目状态:未结题
- 来源:
- 关键词:AgonistAmplifiersAntibiotic TherapyAntibioticsAttenuatedBindingBiological AssayBiosensorBordetella pertussisCause of DeathCell SeparationCellsCessation of lifeCharacteristicsCommunicable DiseasesComplexCore FacilityCoughingCytotoxinDataDevelopmentDiseaseElementsEquilibriumFamilyFlow CytometryGenesGoalsGram-Negative BacteriaImmunization ProgramsInfantInflammationInflammatoryInflammatory ResponseKineticsKnockout MiceLicensingLigandsLungMass VaccinationsMeasuresMediatingMusMyeloid CellsPapioPathogenesisPathologyPattern recognition receptorPeptidoglycanPertussisPharmaceutical PreparationsProteinsPublic HealthPulmonary InflammationPulmonary PathologyReceptor ActivationRecombinantsRoleSphingosine-1-Phosphate ReceptorTestingTherapeuticTissuesTracheaVirulence FactorsWorkairway epitheliumantimicrobialantimicrobial peptideassociated symptombactericidecell typecytokinecytotoxicdifferential expressionin vitro Assayinhibitorinsightnext generationnovel therapeuticspeptidoglycan monomerpeptidoglycan recognition proteinpreventreceptorresponsesingle-cell RNA sequencingtranscriptomics
项目摘要
Project Summary
Recent years have seen a re-emergence of pertussis as a major public health concern, despite
successful mass vaccination programs. Critical pertussis disease causes over 150,000 deaths annually.
Antibiotics are only effective if given before the onset of the characteristic cough. For these reasons, there is an
urgent need for the development of new treatments.
The long-term goal of our group is to develop anti-pertussis therapeutics. Our central hypothesis is that
targeting tissue damage and inflammation induced by bacterial virulence factors will have a greater benefit than
traditional bactericidal therapies. We have demonstrated the potential of sphingosine-1-phosphate receptor
(S1PR) agonists in reducing pulmonary inflammation in mice and baboons. The objective of this work is to
understand the beneficial elements of the S1PR agonist-mediated response to guide the next generation of anti-
microbials. We identified two peptidoglycan recognition proteins (PGLYRP), -1, and -4 an antimicrobial protein,
as differentially regulated by S1PR agonism. PGLYRPs elicit bactericidal activity through interactions with
peptidoglycan (PGN). PGYLRP1 but not PGLYRP4 can stimulate inflammatory responses following PGN
binding. We hypothesize that PGLYRP4 competes with PGLYRP1 to mediate inflammatory responses. Further,
we propose that this is mediated by inhibition of host triggering receptor on myeloid cells 1 (TREM1).
TREM-1 is an amplifier of inflammatory responses. It is upregulated following pattern recognition receptor
activation and its activity amplifies inflammatory cytokine expression. TREM-1 ligands include PGLYRP1-PGN
complexes. TREM-1 expression is reduced by S1PR agonism and inhibitor treated mice show reduced
inflammatory pathology following B. pertussis infection. We hypothesize that TREM-1 acts as a checkpoint
between beneficial bacterial control and detrimental inflammatory pathology.
项目摘要
近年来,百日咳作为一个主要的公共卫生问题重新出现,尽管
成功的大规模疫苗接种计划。严重的百日咳每年造成15万多人死亡。
抗生素只有在特征性咳嗽发作前使用才有效。由于这些原因,
迫切需要开发新的治疗方法。
我们小组的长期目标是开发抗百日咳疗法。我们的核心假设是,
靶向由细菌毒力因子诱导的组织损伤和炎症将具有比
传统的杀菌疗法。我们已经证明了鞘氨醇-1-磷酸受体的潜力
(S1 PR)激动剂在减少小鼠和狒狒的肺部炎症中的作用。这项工作的目标是
了解S1 PR激动剂介导的反应的有益因素,以指导下一代抗-
微生物我们鉴定了两种肽聚糖识别蛋白(PGLYRP),-1和-4,一种抗菌蛋白,
受S1 PR激动作用的差异调节。PGLYRPs通过与以下物质的相互作用引发杀菌活性:
肽聚糖(PGN)。PGYLRP 1而不是PGLYRP 4可以刺激PGN后的炎症反应
约束力我们假设PGLYRP 4与PGLYRP 1竞争介导炎症反应。此外,本发明还
我们提出这是通过抑制髓样细胞上的宿主触发受体1(TREM 1)介导的。
TREM-1是炎症反应的放大器。它在模式识别受体
其活化和活性放大炎性细胞因子表达。TREM-1配体包括PGLYRP 1-PGN
配合物TREM-1表达通过S1 PR激动而降低,并且抑制剂处理的小鼠显示降低的TREM-1表达。
B.百日咳感染我们假设TREM-1作为检查点
有益的细菌控制和有害的炎症病理之间的关系。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ciaran Skerry其他文献
Ciaran Skerry的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ciaran Skerry', 18)}}的其他基金
Pertussis inflammation is mediated by a balance between peptidoglycan recognition proteins-1 and -4
百日咳炎症是由肽聚糖识别蛋白-1 和 -4 之间的平衡介导的
- 批准号:
10416387 - 财政年份:2022
- 资助金额:
$ 38.63万 - 项目类别:
相似海外基金
SBIR Phase II: Thermally-optimized power amplifiers for next-generation telecommunication and radar
SBIR 第二阶段:用于下一代电信和雷达的热优化功率放大器
- 批准号:
2335504 - 财政年份:2024
- 资助金额:
$ 38.63万 - 项目类别:
Cooperative Agreement
Interferometric and Multiband optical Parametric Amplifiers for Communications (IMPAC)
用于通信的干涉式和多频带光学参量放大器 (IMPAC)
- 批准号:
EP/X031918/1 - 财政年份:2024
- 资助金额:
$ 38.63万 - 项目类别:
Fellowship
Josephson Parametric Amplifiers using CVD graphene junctions
使用 CVD 石墨烯结的约瑟夫森参量放大器
- 批准号:
EP/Y003152/1 - 财政年份:2024
- 资助金额:
$ 38.63万 - 项目类别:
Research Grant
Semiconductor-based Terahertz Traveling Wave Amplifiers for Monolithic Integration
用于单片集成的半导体太赫兹行波放大器
- 批准号:
2329940 - 财政年份:2023
- 资助金额:
$ 38.63万 - 项目类别:
Standard Grant
OPTIME-PA: Optimal MMIC Design of E-Band Power Amplifiers for Satcom using Dedicated Measurements and Non-Linear Modelling
OPTIME-PA:使用专用测量和非线性建模的卫星通信 E 频段功率放大器的最佳 MMIC 设计
- 批准号:
10075892 - 财政年份:2023
- 资助金额:
$ 38.63万 - 项目类别:
Collaborative R&D
Optical Glass Amplifiers for High Capacity Networks
用于高容量网络的光学玻璃放大器
- 批准号:
538379-2018 - 财政年份:2022
- 资助金额:
$ 38.63万 - 项目类别:
Collaborative Research and Development Grants
Investigating the function of ZU5 domain-containing proteins as amplifiers of caspase activation
研究含有 ZU5 结构域的蛋白质作为 caspase 激活放大器的功能
- 批准号:
10681326 - 财政年份:2022
- 资助金额:
$ 38.63万 - 项目类别:
Investigating the function of ZU5 domain-containing proteins as amplifiers of caspase activation
研究含有 ZU5 结构域的蛋白质作为 caspase 激活放大器的功能
- 批准号:
10621402 - 财政年份:2022
- 资助金额:
$ 38.63万 - 项目类别:
Broadband Digital Doherty Amplifiers for Sub-6 GHz 5G wireless Applications
适用于 6 GHz 以下 5G 无线应用的宽带数字 Doherty 放大器
- 批准号:
573452-2022 - 财政年份:2022
- 资助金额:
$ 38.63万 - 项目类别:
Alliance Grants
TALENT – Tapered AmpLifiErs for quaNtum Technologies
人才 — 量子技术的锥形放大器
- 批准号:
10032436 - 财政年份:2022
- 资助金额:
$ 38.63万 - 项目类别:
Collaborative R&D














{{item.name}}会员




